Post by
SrPlata on Oct 27, 2021 8:16pm
Steps on getting to $20 USD
First off I realize we are a long way to $20, Yes I know that first we have to get to $3,4,5 etc first and I am not looking for it overnight (unless they is a buyout)
First step Get Peer review from independent 3rd party on P2 data stock goes to $3to $4
Second step Release P2 trial data if shows no safety issues and efficacy, like I believe it will $5 to $6
Third Step Health Canada gives go ahead to enter P3 $6 to $7, This is assuming they have no adverse issues with the data
Fourth Step Do nationwide media campaighn to get the out IE give CEO and CMO give interviews in Canada and Possibly in US on Financial channels. They did this for P2 rollout why not a bigger one for P3 . $8 to $9
Fifth Step This would be Wall Street putting out research on Arch Biopartners, This would open up a whole new audience who has not heard of Arch and the story with a higher price target $10 $12
Sixth Step Assuming Wall St is covering Arch as noted above then they put out an offering to raise capital for a P3 for Kidneys (Which is a lot bigger worldwide market than Lungs) some estimates $20 billion. I have been told that Wall St has been looking for a bio tech that can adddress this huge market of AKI. $13 to $15
Seventh Step If all the above happens then we will get institutionall sponsorship IE are market cap will be such that we will be included in some of the indexes like Russell 2000 also ETF specific Bio Tech, also we will meet criteria for Mutual Fund ownership etc. $16 to $18
Eighth Step P3 trial data is showing great results $19 to $20
Ninth Step Big Pharma has to have us WE NAME OUR PRICE
If you add in that we are under the Radar of most investors and our tight share structure and where we trade now. I may be conservative or aggressive on the above steps. First step has to happen or the other steps won't
This is not going to happen overnight and willl take some time. Anything can happen feel free to add comments and criticism of the above